Haleon plc (HLN)

Nov 9, 2026

Shares of Haleon PLC (HLN) experienced a decline of 2.39% on Monday, closing at £3.31, despite a general rise in the stock market where the FTSE 100 Index (UKX) increased by 1.02%. The company's stock is now 23.71% below its 52-week high of £4.34, which was reached on October 15th.

Nov 4, 2026

Jefferies has downgraded Haleon PLC (LSE:HLN, NYSE:HLN) from 'buy' to 'hold', citing the need for lower prices and increased marketing investment to boost sales outside of oral health products. The brokerage also cut its price target for Haleon by 20% to 320p and reduced its 2027 earnings per share and organic sales growth forecasts due to weak sales, a planned margin reset, and regulatory issues in China affecting Centrum sales. Jefferies expects the company's valuation multiple to remain around 15 times earnings until recovery evidence emerges in the second half of 2027.

Nov 2, 2026

Berenberg has downgraded Haleon from 'buy' to 'hold' and cut its price target, following a weaker-than-expected top-line performance in Q3 and reduced growth visibility. The brokerage cited inconsistent revenue delivery, a fresh guidance cut, and higher execution risk as reasons for the downgrade. Haleon's organic sales growth for FY26 is now expected to be around 2.5%, down from previous estimates.

Oct 29, 2026

Haleon has initiated a £500 million share buyback program to reduce its share capital and fulfill obligations related to employee share plans. The company has engaged Citigroup Global Markets to execute the buyback on various exchanges, with the program expected to conclude by February 19, 2027. This move reflects Haleon's confidence in its financial position and commitment to delivering shareholder returns.

Oct 29, 2026

Haleon Plc (NYSE: HLN) shares fell to a 52-week low after the company cut its full-year organic revenue growth guidance to roughly 2.5% from a previous range of 3%-5%. The reduction was attributed to softness in categories like cough, cold, and flu consumption, despite strong performance in Oral Health and progress in North America. Additionally, the company faces regulatory hurdles in China and is accelerating a new tax framework rollout in Brazil, which will impact fourth-quarter net revenue.